Stable Cell Lines for rAAV Production via Segmentation
Solution Overview
Problem
Current methods for producing recombinant adeno-associated virus (rAAV) virions are inefficient, expensive, and result in variable product quality due to toxicity issues and low encapsidation of therapeutic payloads.
Innovation Solution
Development of stable cell lines capable of conditionally producing rAAV virions with an expressible payload, using polynucleotide constructs that can be integrated into the genome or present as plasmids, allowing for transient transfection and inducible production of rAAV virions upon addition of triggering agents, enhancing homogeneity and control over production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If helper-virus-free transient transfection of multiple plasmids is used for rAAV production, then production capacity can be increased, but manufacturing efficiency decreases and production cost increases
Solution Approach 1:
The patent divides the rAAV production system into multiple stable cell lines, each expressing specific components (Rep/Cap proteins in one line, helper functions in another, payload in a third). This segmentation allows each cell line to be optimized independently and eliminates the need for simultaneous plasmid transfection, thereby improving manufacturing efficiency while maintaining high production capacity.
Solution Approach 2:
The patent establishes stable cell lines that constitutively express necessary AAV components (Rep/Cap proteins and helper functions) before production is needed. This preliminary action eliminates the time-consuming transient transfection step and allows for rapid, efficient production when triggered, resolving the contradiction between production capacity and manufacturing efficiency.
2Quantity of substance
If multiple plasmids are transiently transfected into adherent cell lines, then rAAV virions can be produced, but product quality becomes variable with low encapsidation levels
Solution Approach 1:
By separating the expression of different AAV components into distinct stable cell lines, the patent ensures consistent expression levels of Rep/Cap proteins, helper functions, and payload. This segmentation eliminates the variability associated with transient transfection and improves encapsidation efficiency, thereby enhancing manufacturing precision while maintaining virion production.
Solution Approach 2:
The patent uses transient transfection only for the payload plasmid in a stable cell line background, rather than transiently expressing all components. This approach maintains the stability and homogeneity of the production system while still allowing flexible payload changes, improving product quality consistency.
3Productivity
If AAV Rep protein and adenoviral helper protein are constitutively expressed, then rAAV production can occur, but toxicity to host production cells increases
Solution Approach 1:
The patent segments the expression of toxic components into separate stable cell lines that do not co-express all toxic proteins simultaneously. The Rep/Cap cell line expresses only AAV structural proteins, while the helper cell line expresses adenoviral functions, reducing cumulative toxicity to host cells while maintaining rAAV production capability.
Solution Approach 2:
The patent introduces a conditional induction system using tetracycline-responsive elements and Cre/loxP recombination as intermediaries. These intermediaries allow controlled activation of rAAV production only when needed, minimizing the duration of toxic protein expression and reducing host cell damage while maintaining productivity.
Data Source
AI summary
Described herein are compositions and methods of using stable cells lines in combination with transient transfection to produce recombinant AAV (rAAV).